trial

Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167

NCTId NCT02260830
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 28 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2015-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-08
Primary completion
2015-03
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Lu AF11167

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

1 total
Nottingham, United Kingdom

Facts & assertions

4 sourced
Enrollment
28
Phase
PHASE1
Primary Completion Date
2015-03
Status
COMPLETED
relationships
The graph out of here
drug
Lu AF11167
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication